Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study.

摘要: PURPOSE High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant delays skeletal events, yet whether or not also delay metastastic development remains to be determined. MATERIALS AND METHODS A total 140 high-risk who were definitive and had clinically organ-confined disease suffered from recurrence administered intravenous (IV) clodronate. treated with a radical retropubic prostatectomy (RP) curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added the prevent bone demineralization. Twenty-six out 60 operated cases 45 80 irradiated received bisphosphonate. length time until first metastasis recorded analyzed. RESULTS No statistical difference found for type primary (RP RTx) on (95% confidence interval [CI], 0.40 2.43; p=0.98). However, there clear advantage favoring group that bisphosphonate (p<0.001). addition delayed appearance by seven-fold CI, 3.1 15.4; p<0.001). CONCLUSION Treatment in experiencing increase specific antigen level after treatment.